Sergio Contreras

Internal medicine/ Oncology
Todo tiene un orden, solo debes darle un sentido 🎲

[Dr. David Kershenobich S @DKershenobich]

El Centro Nacional de la Transfusión Sanguínea convoca al 2do Maratón Nacional para la Donación de Sangre con el fin de fortalecer la cultura de donación altruista en el país.

Recordemos que la sangre no se puede fabricar en laboratorios, depende 100% de los donadores.

[Maite Bourlon @BourlonMaite]

Congrats to @PaolaVS94 for receiving the @ASCO #asco2026 IDEA Award!!!!

We are proud of you at @INCMNSZ_Uronco and all our friends and colleagues big achievements!’

@hafaydeefe @jacquealcalde1 @lalo_glez8a @INCMNSZ_Ensena @INCMNSZ_DirInv

[Dr. David Kershenobich S @DKershenobich]

La llegada de la vacuna para el VSR es un hito para la salud en México, ya que más del 40% de las infecciones de vías respiratorias en la infancia se atribuyen a este virus. Al aplicar la vacuna a mujeres embarazadas brindamos protección a la madre y al recién nacido.

[Maite Bourlon @BourlonMaite]

*IDEA AWARD* One of the most fabolous @ASCO @ConquerCancerFd awards for LMIC trainees or early career oncologists!

—> congrats to recipiente @PaolaVS94
—> take advantage of this wonderful program

[Tejas Patil @TejasPatilMD]

🙏🏽It was an absolute pleasure to discuss treatment strategies for #EGFR and #HER2 #NSCLC and importance of optimal #biomarker testing in lung cancer @cancerGRACE earlier this year!

📽️VIDEO (@YouTube) links below!

1⃣ Biomarkers & Targeted Therapies: https://t.co/mk69CGBZGY

2⃣ Treatments for #EGFR NSCLC: https://t.co/ATFR1IvR7O

3⃣ Treatments for #HER2 NSCLC: https://t.co/ye6bIgGU3J

4⃣ Real world biomarker testing: https://t.co/85AufqjXM3

@lcsmchat @OncoAlert @OncLive @LungCancerRx @EGFRResisters @EgfrUk @EGFRSummit @Exon20Group @OncogeneCancer @YoungLungCancer @lcfamerica

[Dr. David Kershenobich S @DKershenobich]

Nos reunimos con el Organismo Internacional de Energía Atómica (OIEA) para reforzar la cooperación en servicios de imagenología, diagnóstico y tratamiento oportuno de cáncer.

Esta alianza promueve la investigación e innovación en nuestro país.

https://t.co/20ddFUlIYW

[Toni Choueiri, MD @DrChoueiri]

This worries me. AI can only become better and better to fool us all. We lead by trust + integrity; we need more than ever better tools + accountability. This even passed @NEJM before being retracted….kudos to @NEJM editors for catching this shortly!

https://t.co/GcjbHGnSlW

[Enrique Soto @EnriqueSoto8]

Super excited that the @CUCancerCenter now has a webpage highlighting how we care for older adults with cancer!

Personalized, multidisciplinary, and focused on what matters most to patients 💪

Check it out 👇

https://t.co/HA9AxvdaEM

[Sergio Contreras @SergioContg]

“Did pandemics truly change pulmonary embolism rates in oncology patients—or are we seeing reference bias and hidden collateral effects behind these uneven proportions?” https://t.co/qkL7tYyOel

[Alfredo Covarrubias, MD. BSND. @CovarrubiasMD]

No te lo pierdas

https://t.co/2iRsnRu2rJ

[Dr. Ariella Hanker @AriellaHanker]

Excited to be an #AACR26 ambassador and have the privelege of attending my 11th in person @aacr annual meeting! It’s always an inspiring experience that leaves me refreshed and motivated. 2025- the year of #ecDNA and #KRAS, 2026- #AI and new drug types?
@utswcancer

[Dr. Ragosán @DrRagosan]

La NCCN agrega modelos de IA para mejorar la predicción del riesgo de CM

🧪 Modelos de IA+MG integrados en la NCCN para análisis automatizado de mastografías.
🚀 Predicción de riesgo a 5 años en Px sin FR
📉 Riesgo ≥ 1.7% = "Riesgo Aumentado"

🔗 La noticia completa aquí: https://t.co/T0do4wdTDJ

@DrRagosan @ScienceLinkOnco
#CancerDeMama #MedTwitter #Oncologia #NCCN #IA
⛲ https://t.co/xGj88fhJtT

[Dr. José Sifuentes Osornio @DrJoseSifuentes]

Le envío una felicitación muy especial al Dr. Alberto Ávila Funes por este merecido reconocimiento. Enhorabuena!

[SALUD México @SSalud_mx]

El secretario de Salud, David Kershenobich, y la embajadora del Reino Unido en México, Susannah Goshko, sostuvieron un encuentro para fortalecer la cooperación bilateral en salud, centrada en la modernización del sistema mediante la innovación tecnológica, el fortalecimiento regulatorio y la promoción de oportunidades de inversión en México.
🇬🇧🫱🏽‍🫲🏼🇲🇽

En la reunión participó el subsecretario de Integración Sectorial y Coordinación de Servicios de Atención Médica, Eduardo Clark, así como los titulares del Consejo de Salubridad General, COFEPRIS y CCINSHAE. 🩺

[Oscar Arrieta @ogarrieta]

We published in lung cancer a review of respiratory sarcopenia in the area of ​​thoracic oncology. https://t.co/1dIwmln0ql
Respiratory sarcopenia is a clinically relevant but incompletely defined. A feasible, strength-first screening can identify patients who may require closer peri-operative attention. Imaging surrogates and diaphragm ultrasound provide additional contextual information when available. While reported associations with complications and survival are suggestive, they are uneven due to heterogeneity in definitions, thresholds, and protocols. Within enhanced recovery pathways, inspiratory muscle training can be considered a component of multimodal optimization for selected patients. We emphasize that careful, claims-disciplined use of RS metrics, as a complement to established risk tools and clinical judgment, is reasonable. Future priorities include harmonizing measurement protocols and deriving thoracic-specific thresholds to determine who benefits most and how best to deploy resources effectively. @detectoincan @incanMX @JordiRemon @MarisolNeumo @JennyTurcott @Ecaballep @LungCancerEu @AndresFCardonaz

[Maite Bourlon @BourlonMaite]

Happy to see the poster walks leads for today!!
@raymanneh 🇨🇴
@DrRanaMcKay 🇺🇸
Will lead the #kidneycancer discussion @GU26 @ASCO

Optimal time ICIS, Genmic dedifferentiation & integrative genomic landscape @OncoAlert @UrologyTimes @jrgralow

[Maite Bourlon @BourlonMaite]

LAST DAY!! #GU26 @asco 📅

⏰Awaiting @katy_beckermann discussion of the LITESPARK studies! starting 8:10 am

- Are we going to change treatment sequencing in mRCC? @motzermd
- Is there a new standard for adjuvant ccRCC? @DrChoueiri

Don´t miss this evvent @Larvol @OncoAlert

[Maite Bourlon @BourlonMaite]

DAY3⃣ @asco #GU26 #kidneycancer The BELZUTIFAN story!

🔴LITESPARK-011 Belzu + lenva vs cabo for aRCC after PDL1
🔵LITESPARK-022 Adjuvant pembro+belzu vs pembro in localized ccRCC @DrChoueiri
🟠LITESPARK-024 dose escalation of belzu + palbo

#ASCOVoices @OncoAlert @oncodaily

[Maite Bourlon @BourlonMaite]

DAY 2: #Urothelialcancer @asco #GU26

🟢 KEYNOTE-B15 EV + pembro cisplatin-eligible MIBC 📢 TOP abstract @MattGalsky

🧑‍🔬 RC48G001 P2 disitamab HER2+ previously tx aUC @tompowles1

🌅 SunRISe-2 Gem-intravesical +cetre vs ChemoRT in MIBC @AndreaNecchi

@OncoAlert @oncodaily

[Maite Bourlon @BourlonMaite]

Day 1: Prostate 8:15 am @ASCO #GU26
3️⃣ studies w updated OS

✅ PEACE 3: enza w or w/o radium-223 in mCRPC
✅ BRCAway: abi vs Olaparib vs abi+Olaparib mCRPC & DNA repair def
✅ ASCENDE-RT ⏩ 15 years external beam RT boost vs brachy in localized PC
@OncoAlert @UrologyTimes